MELK inhibitors (Cancer Therapeutics CRC)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameMELK inhibitors (Cancer Therapeutics CRC)
Drug Alias Namematernal embryonic leucine zipper kinase inhibitors (Cancer Therapeutics CRC)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMaternal embryonic leucine zipper kinase inhibitors
TargetsMaternal embryonic leucine zipper kinase
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryAustralia and New Zealand
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesCancer Therapeutics CRC Pty Ltd
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesCancer Therapeutics CRC Pty Ltd
Active IndicationsN/A
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A